A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

December 31, 2017

Study Completion Date

February 7, 2020

Conditions

Acute Lymphoblastic LeukemiaLeukemia, Myelocytic, AcuteChronic Myelogenous Leukemia With Crisis of Blast Cells

Interventions

DRUG

BEZ235

A minimum of 3 dose levels

Trial Locations (1)

Johann Wolfgang Goethe University Hospitals, Frankfurt am Main